The word ‘pulmonary’ translates to lung while ‘fibrosis’ means scarring. Scarring of the lung occurs in the soft tissue that supports the air sacs. There are estimated 130-200 similar diseases with matching characteristics that result in scarring.
In the condition Idiopathic pulmonary fibrosis (IPF) the lung tissue thickens and becomes hard. Even though the air sacs themselves are not affected by this, they do get compressed by this interstitial scar tissue.
As the condition worsens, breathing becomes progressively difficult. The condition is fatal with a life expectancy of three to five years from time of diagnosis.
A vast majority of the idiopathic pulmonary fibrosis are called not treatable by the doctors. The disease is very difficult to predict, it is not preventable, and can’t even be diagnosed in most cases because the different variations of the disease take radically varying pathways making diagnosis difficult. Most typically it is linked to smoking.
Many types of fibrosis respond to immune suppressant drugs since the immune system has a big affiliation with scarring and inflammation. Unfortunately such treatments come at the risk of high toxicity in addition to other side effects.
The patients using immune suppressant drugs also have to make use of blood thinning drugs as well as supplemental oxygen due to decreased oxygen intake and the danger of clots from the scar tissue of lungs.
The ever increasing knowledge about enzymes and their role in the human body, it is now known that scar tissue accumulates because there is insufficient production of enzymes needed to remove it.
Due to the ageing process and the modern diet, the human body’s repair systems are thrown out of balance. There is increased production of fibrin which gets packed into every injury creating surplus of scarring.
Taking supplements of certain enzymes and thereby restoring the balance of enzymes, it is possible to remove the excess scar tissue without harming the healthy tissue.
Serrapeptase is a naturally occurring enzyme that has been showing positive results in the treatment of chronic inflammation and removal of mucus from lungs in cases of conditions like emphysema and Bronchiectasis.
In one particular study serrapeptase was compared to trypsin, chymotrypsin and pronase. It was the most effective of all compounds used in reducing inflammation, removing mucus and scar tissue in rat models in which these conditions were induced.
In a clinical study human volunteers were given 30mg dose daily for four week to reduce phlegm and the frequency of coughing form patients suffering from emphysema and COPD.
Researchers summarised that serrapeptase can play a beneficial role in clearing mucus from airways and lungs.